This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

COMPARISON OF RESULTS IN ONE HUNDRED AND EIGHTY-EIGHT CASES WITH THOSE OF THE COOPERATIVE CLINICAL GROUP

LOUIS CHARGIN, M.D.; WILLIAM LEIFER, M.D.; THEODORE ROSENTHAL, M.D.

Arch Derm Syphilol. 1939;40(2):208-217.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Opinion is almost unanimous that arsphenamine (diaminodihydroxyarsenobenzene hydrochloride) is to this day the most effective arsenical in the treatment of early syphilis. However, since its first introduction it has been apparent that because of its by-effects and the difficulty of its preparation and administration it is not a practicable drug for use by the general practitioner. Efforts have been made, and are still being made, to develop a more satisfactory arsenical. These efforts have resulted in the introduction of useful but far from ideal drugs, the most important being neoarsphenamine, silver arsphenamine and sulfarsphenamine. The need for a drug of high therapeutic efficiency, minimal toxicity and facility of preparation and administration is of vital importance for the ultimate eradication of syphilis. Among the drugs recently introduced and said to meet more closely the aforementioned criteria is mapharsen, for which the following claims¹ have been made: It is a pure . . . [Full Text PDF of this Article]

Author Affiliations
NEW YORK

From the Central Clinic, Bureau of Social Hygiene, Department of Health of the City of New York, Dr. John L. Rice, Commissioner.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?